Floatz logo

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)

Refractory Anemia With Excess Blasts

National Cancer Institute (NCI)protein_peptidePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Refractory Anemia With Excess Blasts cohort.

Asset / SponsorPhaseRating
Monomethyl Fumarate
Fred Hutchinson Cancer Center
Phase 2BBB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BBB
Cytosin-Arabinosid
University of Southern California
Phase 3BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BB

View all 34 →

Same molecule, other indications

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) is also rated in:

Adult Acute Lymphocytic LeukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
L1 Childhood Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Untreated Childhood Acute Myeloid Leukemia and Other Myeloid MalignanciesDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →